Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed PlcStock Exchange Release4 December 2023 at 10.30, Helsinki
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc ("Optomed" or the "Company") has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from Cenova Capital ("Notifier"). According to the notification, the total holdings in Optomed shares and votes held by Notifier is 3.81 per cent of all of the registered shares in Optomed on 1 December 2023.
The total number of the Company's registered shares amounts to 18,130,397 shares. Each share entitles to one vote.
The total position of Notifier subject to the notification:
+----------------+----------+------------------+-----+----------------------+
| |% of |% of shares and |Total|Total number of shares|
| |shares and|voting rights |of |and voting rights of |
| |voting |through financial |both |issuer |
| |rights |instruments (total|in % | |
| |(total |of B) |(A+B)| |
| |of A) | | | |
+----------------+----------+------------------+-----+----------------------+
|Resulting |3.81 % |- |3.81 |18 130 397 |
|situation on the| | |% | |
|date on | | | | |
|which threshold | | | | |
|was crossed or | | | | |
|reached | | | | |
+----------------+----------+------------------+-----+----------------------+
|Position of |9.96 % |- |9.96 | |
|previous | | |% | |
|notification | | | | |
|(if applicable) | | | | |
+----------------+----------+------------------+-----+----------------------+Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
+------------+-----------------+----------------+-----------------+-----------+
|Class/type |Number of shares and voting rights|% of shares and voting rights|
|of shares | | |
| | | |
|ISIN code | | |
+------------+-----------------+----------------+-----------------+-----------+
|Direct |Indirect |Direct |Indirect |
|(SMA 9:5) |(SMA 9:6 and 9:7)|(SMA 9:5) |(SMA 9:6 and 9:7)|
+------------+-----------------+----------------+-----------------+-----------+
|FI4000410881|- |691 532 | |3.81 % |
+------------+-----------------+----------------+-----------------+-----------+
|SUBTOTAL A |691 532 |3.81 % |
+------------+-----------------+----------------+-----------------+-----------+Information in relation to the person subject to the notification obligation as contained in the notification
The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
+-----------------+----------------+-----------------------------+------------+
|Name |% of shares and |% of shares and voting rights|Total of |
| |voting rights |through financial instruments|both |
+-----------------+----------------+-----------------------------+------------+
|Cenova China |0% of shares and|- |0% of shares|
|Healthcare GP iv |100% of voting | |and 100% |
|Limited |rights | |voting |
| | | |rights of |
| | | |Cenova China|
| | | |Healthcare |
| | | |Fund IV, |
| | | |L.P. |
+-----------------+----------------+-----------------------------+------------+
|Shanghai Cenova |1% of shares and|- |1% of shares|
|Bioventure Equity|100% of voting | |and 100% |
|Investment Fund |rights | |voting |
|Management | | |rights of |
|Enterprise | | |Shanghai |
| | | |Cenova |
| | | |Innovation |
| | | |Venture Fund|
| | | |(Limited |
| | | |Partnership)|
+-----------------+----------------+-----------------------------+------------+
|Shanghai Cenova |100% | |100% of |
|Innovation | | |Alnair |
|Venture | | |Investment |
|Fund (Limited | | | |
|Partnership) | | | |
+-----------------+----------------+-----------------------------+------------+
| |- |- |- |
+-----------------+----------------+-----------------------------+------------+Further enquiries
Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com,+358(0)50562 4077.
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases, such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.
www.optomed.com